GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » Cash Conversion Cycle

Renalytix (Renalytix) Cash Conversion Cycle : -361.25 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Renalytix Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Renalytix's Days Sales Outstanding for the three months ended in Mar. 2024 was 164.08.
Renalytix's Days Inventory for the three months ended in Mar. 2024 was 77.74.
Renalytix's Days Payable for the three months ended in Mar. 2024 was 603.07.
Therefore, Renalytix's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was -361.25.


Renalytix Cash Conversion Cycle Historical Data

The historical data trend for Renalytix's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Cash Conversion Cycle Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Conversion Cycle
Get a 7-Day Free Trial - - -675.74 -144.19 -149.29

Renalytix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -318.38 -184.42 -264.51 -367.44 -361.25

Competitive Comparison of Renalytix's Cash Conversion Cycle

For the Health Information Services subindustry, Renalytix's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's Cash Conversion Cycle Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Renalytix's Cash Conversion Cycle falls into.



Renalytix Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Renalytix's Cash Conversion Cycle for the fiscal year that ended in Jun. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=89.94+127.74-366.97
=-149.29

Renalytix's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=164.08+77.74-603.07
=-361.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix  (NAS:RNLX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Renalytix Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Renalytix's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix (Renalytix) Business Description

Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Executives
Howard Jr Doran officer: Chief Business Officer C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain officer: President NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc. 10 percent owner 150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills director, 10 percent owner C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling officer: Chief Financial Officer C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc. 10 percent owner ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount 10 percent owner ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming director, officer: Chief Technical Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough director, officer: Chief Executive Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE

Renalytix (Renalytix) Headlines

From GuruFocus

Renalytix announces a c.$20.3 million private placement

By Stock market mentor Stock market mentor 02-08-2023